Viking Therapeutics To Host Key Opinion Leader Event To Discuss Musculoskeletal Therapeutics In Hip Fracture And Other Settings
Published: Sep 25, 2017
SAN DIEGO, Sept. 25, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will host a key opinion leader (KOL) presentation and webcast to highlight the current unmet need in post-fracture therapy and discuss the company's lead program VK5211 for the treatment of patients following hip fracture surgery. The event details are as follows:
Monday, October 9, 2017
152 W. 51st Street @ 7th Avenue
The event will feature presentations from four speakers, each with significant experience in the development of novel musculoskeletal therapeutics or in the treatment of hip and other fracture patients:
- Keith Marschke, Ph.D., VP, Biology, Ligand Pharmaceuticals
- Jay Magaziner, Ph.D., Epidemiology and Biostatistics Professor and Chair, Department of Epidemiology and Public Health, University of Maryland School of Medicine
- Neil Binkley, M.D., Professor, Department of Medicine - Geriatrics; Co-Director, Osteoporosis Clinical Center and Research Program, Associate Director, Institute on Aging, University of Wisconsin School of Medicine and Public Health
- Jack Guralnik, M.D., Ph.D., MPH, Professor, Department of Epidemiology and Public Health, University of Maryland School of Medicine
A light lunch will be served at conclusion of the event.
Viking recently announced that enrollment has been completed in the company's ongoing Phase 2 clinical trial of VK5211 in patients recovering from hip fracture surgery. VK5211, the company's lead program for muscle and bone disorders, is an orally available, non-steroidal selective androgen receptor modulator (SARM) designed to selectively stimulate muscle and bone formation with reduced activity in peripheral tissues such as skin and prostate. The company believes these characteristics may provide important benefits to patients recovering from hip fracture.
The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled, parallel group study designed to evaluate the efficacy, safety and tolerability of VK5211 in patients recovering from hip fracture surgery. A total of 108 patients have been randomized to receive once-daily VK5211 doses of 0.5 mg, 1.0 mg, 2.0 mg, or placebo for 12 weeks. The study's primary endpoint will evaluate the effects of VK5211 on lean body mass after 12 weeks of treatment. Secondary and exploratory objectives include assessments of functional performance, quality-of-life, and activities of daily living, as well as safety, tolerability and pharmacokinetics. Viking expects to announce results from this trial in the fourth quarter.
This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Space is limited, please RSVP in advance to attend. To RSVP, please contact Stephanie Diaz at Vida Strategic Partners at email@example.com.
A live and archived webcast of the event will be available on the Investors section of the company's website at http://ir.vikingtherapeutics.com/webcasts-and-presentations.
VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) in Phase 2 development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 belongs to a family of novel orally available, non-steroidal SARM compounds based on tissue-specific gene expression and other functional, cell-based technologies. Viking believes that VK5211 has the potential to produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration. In Phase 1 clinical trials, VK5211 demonstrated statistically significant increases in lean body mass among treated subjects following 21 days of treatment. In a pre-clinical model of osteoporosis, VK5211 demonstrated improvements in bone mineral density, bone mineral content, bone strength, and other measures.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist in Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
This press release contains forward-looking statements regarding Viking Therapeutics, including statements about Viking's expectations regarding its development activities, timelines and milestones, as well as the company's goals and plans regarding VK2809 and VK2809's prospects. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of Viking's product candidate development activities and clinical trials, including those for VK2809; risks that prior clinical and pre-clinical results may not be replicated; and risks regarding regulatory requirements, among others. These forward-looking statements speak only as of the date hereof. Viking disclaims any obligation to update these forward-looking statements.
View original content:http://www.prnewswire.com/news-releases/viking-therapeutics-to-host-key-opinion-leader-event-to-discuss-musculoskeletal-therapeutics-in-hip-fracture-and-other-settings-300524813.html
SOURCE Viking Therapeutics, Inc.